Mineral coatings modulate β-TCP stability and enable growth factor binding and release

Acta Biomater. 2012 Mar;8(3):1117-24. doi: 10.1016/j.actbio.2011.11.028. Epub 2011 Dec 2.

Abstract

β-Tricalcium phosphate (β-TCP) is an attractive ceramic for bone tissue repair because of its similar composition to bone mineral and its osteoconductivity. However, compared with other ceramics β-TCP has a rapid and uncontrolled rate of degradation. In the current study β-TCP granules were mineral coated with the aim of influencing the dissolution rate of β-TCP, and also to use the coating as a carrier for controlled release of the growth factors recombinant human vascular endothelial growth factor (rhVEGF), modular VEGF peptide (mVEGF), and modular bone morphogenetic protein 2 peptide (mBMP2). The biomineral coatings were formed by heterogeneous nucleation in aqueous solution using simulated body fluid solutions with varying concentrations of bicarbonate (HCO(3)). Our results demonstrate that we could coat β-TCP granules with mineral layers possessing different dissolution properties. The presence of a biomineral coating delays the dissolution rate of the β-TCP granules. As the carbonate (CO(3)(2-)) content in the coating was increased the dissolution rate of the coated β-TCP also increased, but remained slower than the dissolution of uncoated β-TCP. In addition, we showed sustained release of multiple growth factors, with release kinetics that were controllable by varying the identity of the growth factor or the CO(3)(2-) content in the mineral coating. Released rhVEGF induced human umbilical vein endothelial cell (HUVEC) proliferation, and mVEGF enhanced migration of mouse embryonic endothelial cells in a scratch wound healing assay, indicating that each released growth factor was biologically active.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bicarbonates / chemistry
  • Bicarbonates / pharmacology
  • Bone Morphogenetic Protein 2* / chemistry
  • Bone Morphogenetic Protein 2* / pharmacology
  • Bone Substitutes / chemistry
  • Bone Substitutes / pharmacology
  • Calcium Phosphates* / chemistry
  • Calcium Phosphates* / pharmacology
  • Cell Line
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Ceramics* / chemistry
  • Ceramics* / pharmacology
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / pharmacology
  • Embryo, Mammalian / cytology
  • Embryo, Mammalian / metabolism
  • Endothelial Cells / cytology
  • Endothelial Cells / metabolism
  • Humans
  • Mice
  • Peptides* / chemistry
  • Peptides* / pharmacology
  • Recombinant Proteins* / chemistry
  • Recombinant Proteins* / pharmacology
  • Umbilical Veins / cytology
  • Umbilical Veins / metabolism
  • Vascular Endothelial Growth Factor A* / chemistry
  • Vascular Endothelial Growth Factor A* / pharmacology
  • Wound Healing / drug effects

Substances

  • BMP2 protein, human
  • Bicarbonates
  • Bone Morphogenetic Protein 2
  • Bone Substitutes
  • Calcium Phosphates
  • Delayed-Action Preparations
  • Peptides
  • Recombinant Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • beta-tricalcium phosphate